Rallybio(RLYB)

Focus: Rallybio is a public-stage biotechnology company focused on oncology and rare hematologic diseases, headquartered in New Haven, CT. The company operates as a clinical-stage developer with minimal revenue and aggressive R&D spending.

Oncology

Profile data last refreshed 13h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Rallybio

AI assessmentNot Hiring

No open roles listed right now. Follow Rallybio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$636K

Pipeline & Clinical Trials

Clinical data collection

Fetal and Neonatal Alloimmune Thrombocytopenia

N/A

Clinical Trials (1)

NCT05345561Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia

N/A

Help build intelligence for Rallybio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage oncology pipeline with Phase 1–2 programs offers exposure to cutting-edge drug development and potential for rapid advancement as programs progress.
Public company status provides equity upside potential and access to capital markets, contrasting with pre-IPO risk.
Highly specialized focus on rare hematologic diseases (FNAIT) represents a niche opportunity in an underserved therapeutic area.

Watch Out For

Severe cash burn ($57.8M net loss in FY 2025, $74.6M in FY 2024) against only $14M cash position indicates runway risk and imminent financing pressure or restructuring.
Recent failed merger attempt (Candid deal) followed by emergency pivot to Avenzo merger (June 2026) signals strategic instability and potential job disruption; New Haven HQ closure announced.
Zero active job openings and minimal headcount data suggest organization may be in transition or contraction post-merger.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Hematology, Immunology

Publications: 11 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Hematology

2 pipeline

Immunology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$636K6%

R&D Spend

$42M(6526%)22%

Net Income

-$58M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Risk Signals

June 2026: Announced HQ closure in New Haven post-failed Candid merger and emergency acquisition by Avenzo; full workforce impact unknown pending integration details.

Merger integration, HQ closure, and failed prior deal suggest significant organizational restructuring and involuntary attrition ahead.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Transfusing HPA-mismatched platelets to mimic fetomaternal hemorrhage elicits fetal/neonatal alloimmune thrombocytopenia.

Blood

2026

PMID:41812187

Structural basis of HPA-1a alloimmunization in FNAIT and allosteric regulation of integrin conformation.